Pfizer Inc., the world’s largest drugmaker, has agreed to buy King Pharmaceuticals Inc. for $3.6 billion in a move to shore up earnings ahead of the looming evaporation of revenue from Lipitor, its biggest product.
*For more on this story, read the full Reuters article.
